CT-1190B

N/A

Report date: 2026/05/21 20:00:22

Base Information

Drug NameCT-1190B
Drug Alias NameCT1190B CAR TCT1190BCT-1190B
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacementsB-lymphocyte antigen CD19 modulatorsB-lymphocyte antigen CD20 modulators
TargetsB-lymphocyte antigen CD19B-lymphocyte antigen CD20
Therapy Area/IndicationsScleroderma, SystemicLupus Erythematosus, SystemicLymphoma, B-Cell +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesCarsgen Biomedicine (Shanghai) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Tongji HospitalYoukaize Biopharmaceutical (Shanghai) Co LtdBeijing GoBroad Hospital +[6] 
Inactive CompaniesN/A
Active IndicationsScleroderma, SystemicLupus Erythematosus, SystemicLymphoma, B-Cell +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A